Department of Research and Development, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Korean Med Sci. 2021 Jan 25;36(4):e28. doi: 10.3346/jkms.2021.36.e28.
Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and fear of dying. Sedatives are mostly respiratory and cardiovascular depressants and do not provide resistance to the pro-inflammatory burst induced by the virus. Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics. This brief communication highlights the benefits potentially provided by ketamine to patients hospitalized for COVID-19 infection.
因 2019 年冠状病毒病（COVID-19）而住院的患者遭受身体损伤和精神压力的双重折磨。呼吸功能不全和心血管紊乱需要进行大多数重症监护干预，但它们也伴随着抑郁状态、悲伤和对死亡的恐惧。镇静剂主要是呼吸和心血管抑制剂，不能抵抗病毒引起的促炎爆发。氯胺酮是一种独特而安全的药物，可实现良好控制的镇静和麻醉，减轻抑郁并缓解自杀念头，而不会抑制呼吸或心血管功能。本简要通讯强调了氯胺酮为因 COVID-19 感染住院的患者可能带来的益处。
